No observations: USFDA inspection at Cipla arm InvaGen New York plant concludes

Published On 2023-10-27 02:00 GMT   |   Update On 2023-11-01 10:53 GMT
Advertisement

Mumbai: Drugmaker Cipla has announced that the United States Food and Drug Administration (USFDA) has concluded inspection with zero Form 483 observations at the manufacturing facility unit 1 and 2 of InvaGen Pharmaceuticals Inc., a wholly-owned subsidiary of the Company located in Hauppauge, Long Island, New York, USA.

The facility was inspected from 16th October 2023 to 25th October 2023.

"We hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility unit 1 and 2 of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the Company) located in Hauppauge, Long Island, New York, USA from 16th October 2023 to 25th October 2023," the Company stated in a recent BSE filing.

Advertisement

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. 

Medical Dialogues team had earlier reported that the New York manufacturing facility of InvaGen Pharmaceuticals Inc. had received the EIR (Establishment Inspection Report) from the US Food and Drug Administration (USFDA) on the classification of the inspection as Voluntary Action Indicated (VAI). Voluntary action indicated (VAI), means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.

Read also: Cipla arm New York facility gets EIR from USFDA

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India. Khwaja Abdul Hamied founded the Company in 1935 in Mumbai.

The Company specializes in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla's 47 manufacturing sites worldwide produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to 86 markets.

Read also: USFDA issues 5 observations to Cipla US arm

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News